Gabapentin ANDA Comparing Tabs To Caps Is Not Complete, Petition Says
Executive Summary
An ANDA for gabapentin tablets that references Warner-Lambert's Neurontin capsules should be treated by the agency as "not substantially complete," an Aug. 12 citizen's petition to FDA argues.
You may also be interested in...
Pfizer Neurontin petition denied
Pfizer citizen petition claiming that gabapentin tablet ANDAs are incomplete if they use Neurontin capsules as reference product is denied by FDA. The agency is not required "to make a determination about bioequivalence or about the approvability or likely approvability of an ANDA prior to accepting the ANDA for review," a Jan. 18 letter says. Such a "substantive" review is only necessary for approval, FDA said. Pfizer filed the citizen petition on the anti-epileptic drug Aug. 12, 1999 (1"The Pink Sheet" Aug. 30, 1999, p. 23)...
Pfizer Neurontin petition denied
Pfizer citizen petition claiming that gabapentin tablet ANDAs are incomplete if they use Neurontin capsules as reference product is denied by FDA. The agency is not required "to make a determination about bioequivalence or about the approvability or likely approvability of an ANDA prior to accepting the ANDA for review," a Jan. 18 letter says. Such a "substantive" review is only necessary for approval, FDA said. Pfizer filed the citizen petition on the anti-epileptic drug Aug. 12, 1999 (1"The Pink Sheet" Aug. 30, 1999, p. 23)...
Warner-Lambert And AHP Plan Protonix Copromotion Agreement
Warner-Lambert and American Home Products intend to complete a co-promotion agreement for AHP's proton pump inhibitor Protonix.